Objective: The purpose of this study was to investigate the effects of acute hypervolemic fluid infusion (AHFI) of 6% hydroxyethyl starch (HES) 130/0.4 or 4% succinylated gelatin (GEL) on hemostasis and the possible mechanisms. Methods: Thirty-six gastric cancer patients were randomized to receive AHFI of either HES, GEL or lactated Ringer's (RL) solution at the rate of 30 mLÁkg À1 Áh À1 from 20 minutes before to 40 minutes after induction of general anesthesia. Results: Group HES and GEL had significantly prolonged PT and aPTT, decreased VIII:C and vWF immediately after AHFI. Statistically prolonged reaction time and coagulation time, and decreased growth angle were seen immediately after HES infusion. Maximum amplitude decreased significantly in group HES and GEL immediately after and 4 hours after AHFI. Conclusion: Gelatin reduced clot quality associated with derangements of fibrin polymerization and HES 130/0.4 delayed initiation of sufficient thrombin generation to convert fibrinogen to fibrin and impaired platelet function.
Introduction
Colloid solutions such as gelatins (GELs) and hydroxyethyl starch (HES) preparations are frequently used as an alternative for blood loss replacement to restore intravascular volume and avoid the risk associated with transfusion of allogenic blood products. 1 However, interference of colloids with the hemostatic system is undesirable in this clinical setting because it may increase the risk of bleeding. The effect of colloids on hemostasis may potentially cause an alteration of the following hemostatic mechanisms 2 : (1) a dilution effect and accompanying changes in blood viscosity and platelet count; (2) an effect on the activity of blood coagulation factors and fibrinolysis; and (3) an influence on platelet function. Gelatin has been considered to have little negative influence on the coagulation progress. However, some studies have also shown that GEL-based hemodilution can alter blood coagulation. [3] [4] [5] [6] Hydroxyethyl starch 130/0.4 is a new median weight HES solution, which has a smaller and more narrowly distributed molecular weight (Mw), a lower molar substitution (MS), a larger ratio of C2/C6 hydroxyethylation (hydroxyethylation at the glucose subunit carbon atoms), and seems to impair the coagulation system less than higher Mw HES solutions. [7] [8] [9] Because detailed information about the 2 artificial colloids on coagulopathology is undefined, we designed this study to investigate the effects on hemostasis of 6% HES 130/0.4 or 4% modified fluid GEL administered for acute hypervolemic fluid infusion (AHFI) during induction of general anesthesia in patients undergoing gastrectomy.
Materials and Methods
After approval by the Ethics Committee of the hospital, 36 American Society of Anesthesiologists (ASA) physical status classification I-II gastric cancer patients of both sexes (23 males, 13 females) aged 28 to 58 years undergoing gastrectomy were enrolled in this study. All patients gave written informed consent. Cardiac insufficiency (New York Heart Association class III-IV), renal insufficiency (serum creatinine >2 mg/dL), altered liver function (aspartate aminotransferase >40 U/L, alanine aminotransferase >40 U/L), preoperative anemia (hemoglobin [Hb] <10 g/dL, hematocrit <30%), preoperative coagulation abnormalities (platelet count <100/nL; activated partial thromboplastin time [aPTT] >70 seconds; fibrinogen <2 g/dL), GEL or hydroxyethyl starch allergy, and the use of anticoagulant or antiplatelet medicine before surgery were defined as exclusion criteria for participation in the study.
All patients received routine monitoring including 5-lead electrocardiography, pulse oximetry, and noninvasive arterial pressure and were sedated with intravenous midazolam 0.04 mg Á kg À1 after arrival at the operating room. The right internal jugular vein was cannulated under local infiltration for central venous pressure monitoring. After 5 minutes, patients were randomly allocated (closed envelopes) to receive AHFI of lactated Ringer's solution (group RL, n ¼ 12), 6% HES 130/0.4 (Voluven, Fresenius Co, Germany; group HES, n ¼ 12) or 4% modified fluid GEL (Gelofusin, B. Braun Co, Germany; group GEL, n ¼ 12) at the rate of 30 mL Á kg À1 Á h À1 from 20 minutes before to 40 minutes after induction of general anesthesia. Ringer's solution was also tested to assist in analyzing the intrinsic effect of colloid molecules on blood coagulation.
General anesthesia was induced with propofol (1.5 mg/kg) and fentanyl (2 mg/kg), and neuromuscular blockade was achieved with vecuronium (0.1 mg/kg). Anesthesia was maintained with isoflurane 1-1.2 minimum alveolar concentration (MAC), fentanyl, and vecuronium and titrated according to the patients' needs. Mechanical ventilation was performed in all patients (fraction of inspired oxygen [FiO 2 ]) to keep oxygen saturation, arterial (SaO 2 ) >95% and end-tidal carbon dioxide concentration between 35 and 40 mm Hg. Esophageal temperature was maintained at >36 C using forced-air warming system. The patients were managed by anesthesiologists who were not involved in the study and were blinded to the grouping.
Hemodynamic measurements included heart rate, mean arterial blood pressure, and central venous pressure. From venous blood samples, standard coagulation variables (prothrombin time [PT] , aPTT, fibrinogen, platelet count, coagulation factor VIII:C, and its carrier glycoprotein von Willebrand factor [vWF]), and thrombelastograph (TEG) were measured prior to AHFI (T0), immediately after AHFI (T1), and 4 hours after AHFI (T2).
Within 4 minutes of sample taking, TEG variables of reaction time (R), coagulation time (K), growth angle (a) and maximum amplitude (MA) were performed using a 4-channel computerized coagulation analyzer TEG (Haemoscope Corp., 5000 series). Thrombelastograph enables a global assessment of hemostatic function. It documents the interaction of platelets with the protein coagulation cascade from the time of the initial platelet-fibrin interaction, through platelet aggregation, clot strengthening, and fibrin cross-linkage to eventual clot lysis. Reaction time is the interval between recording start and the time at which the amplitude of the TEG reaches 2 mm. It is the time necessary for the initial fibrin formation, reflecting the function of the intrinsic coagulation system. Coagulation time is the time from R to a level of clot firmness of 20 mm, and a is measured as the slope of the outside divergence of the tracing from the point of R value. Both are the measurements of the rapidity of fibrin formation and cross-linking, representing the speed at which a thrombus of a certain solidity develops, and are known to be a function of fibrinogen and platelets. Maximum amplitude represents the greatest amplitude reached and reflects the strength of blood clot as a function of platelet and fibrinogen. 10, 11 Statistical analysis was performed with the SPSS 10.0 software package (SPSS, Chicago, IL) and distribution of data was confirmed. All data were presented as mean + SD in absolute values. The data among groups were analyzed by a 1-way analysis of variance (ANOVA) with a leastsignificant difference (LSD) test for multiple comparisons. Differences from the baseline were evaluated by paired t tests. Values were considered significant at P < .05.
Results
The 3 groups did not differ with regard to demographic data, duration of anesthesia, total amount of infusion, intraoperative urine output, and blood loss ( Table 1) . Hemodynamics data are presented in Table 2 .
All standard coagulation variables and TEG data were within normal range and without group differences at T0. As compared with baseline values, PT was significantly prolonged at T1 and T2, as well as aPTT at T1, whereas fibrinogen concentration decreased significantly at T1 and T2 in all groups. Nevertheless, these values remained within the normal range. Prothrombin time was significantly different among the 3 groups at T1, while significant differences of aPTT were seen at T2 between group HES and GEL. Coagulation factor VIII:C decreased significantly at T1 in group HES and GEL, showing significant group differences between group HES and RL. von Willebrand factor decreased significantly at T1 in each group without group differences. Despite the decrease, both values remained within the normal range and returned to baseline data at T2. Hematocrit (HCT) significantly decreased at T1 in all groups and decreased at T2 in group HES and GEL, showing significant group differences among 3 groups. Platelet count in group HES and GEL, although significantly decreased at T1 and T2, was not different than that of group RL (Table 3) .
Initial fibrin formation and fibrin buildup were disturbed (prolonged R and K, and decreased a) immediately after HES administration but not GEL, showing group differences with group RL. Despite these changes, the TEG variables above remained within normal range and returned to baseline data at T2. Clot strength was decreased (decreased MA) significantly in group HES and GEL at T1 and T2, and group differences were detected between both groups and group RL at T2 (Table 4) .
Discussion
Colloid solutions are frequently used to restore and maintain intravascular volume, to stabilize hemodynamic conditions, and to improve tissue perfusion. However, side effects on the coagulation of a colloid-based intravascular volume replacement regimen, which are possibly not only the consequences of dilution of the plasmatic and cellular coagulation factors but also the direct impairment of the coagulation system, have become an increasing concern. 2 Hydroxyethyl starch 130/0.4 is a newly developed third-generation HES solution, which shows favorable physicochemical properties and seems to impair the coagulation system less than other HES solutions.
7-9 However, the major result of the present study showing that HES 130/0.4 induced delayed initiation of hemostasis and impaired clot formation, seeming to induce stronger intrinsic coagulation compromise than GEL immediately after AHFI, is comparable with the result of Fries et al. 12 Namely, HES 130/0.4 induced a marked decrease in the rapidity of clot formation (decreased a) and also an increase in K (prolonged R and K) in addition to a significant decrease in the strength of the clot (decreased MA) as GEL. According to the HCT at T1, hemodilution was most marked in HES-treated patients, which could be an explanation for the lower initial fibrin formation and fibrin buildup by TEG. In addition to the dilutional effect, HES 130/0.4 also exert specific effects on the coagulation system. Hydroxyethyl starch solution caused a vWF type 1-like syndrome 13 characterized by diminished VIII:C levels, which decreased more than might be expected from plasma dilution only. Consequently, we hypothesize that decreased level of factor VIII:C leads to a delay and decrease in generation of sufficient thrombin to convert fibrinogen to fibrin, indicating that HES-mediated effects on clot formation most likely involved alterations in the thrombin-XIIIa-fibrin axis and not just a decrease in activity of a more proximate coagulation factor. Furthermore, vWF-mediated rolling and adhesion of platelets to subendothelial collagen could be diminished by the reduction in VIII/vWF complexes. 13 On the other hand, HES may also induce cellular abnormalities with a decreased agonistinduced expression and activation of platelet surface GPIIb-IIIa by blocking the access of ligands to surface receptors or by an unspecific modification of cytoplasmic membrane structure and a consecutive 13.6 + 2.5 GEL (n ¼ 12) 13.9 + 2.9 14.5 + 2.5 inhibition of the conformational change of GPIIbIIIa, [14] [15] [16] which impairs platelet adhesion to surfacebound fibrinogen and, most importantly, soluble fibrinogen ligand binding between neighboring platelets, causing platelet aggregation. By adhesion and aggregation, platelets form a maze in which plasma can clot without the thrombin being washed away. 17 Hence, it remains to be determined whether extracellular coating of HES impairs platelet procoagulant activity, by modifying the binding of constituents of the prothrombinase and tenase complex to the negatively charged phospholipids exposed on activated platelets, and subsequent thrombin generation. 16 Our results also indicated that in the HES group, however, factor VIII:C, vWF, and the TEG variables of R, K, and a returned to the baseline data 4 hours after AHFI, and blood loss showed no significant differences as compared with the GEL group. It appears closely related to the low in vivo Mw and short halflife of HES 130/0.4 but also to the acute phase reaction after surgical trauma potentially leading to an increase in factor VIII/vWF. Hydroxyethyl starch (HES) is more efficient in initial volume expansion, maintains longer duration of volume expansion, and results in higher hemodilution rate than GEL and RL 18 ; this seems to be the most likely reason for the lower HCT in HES group at T1 and T2.
Gelatins have been considered to not have a significant negative influence on hemostatic competence. 19 However, several recent in vivo and in vitro studies have questioned the generally accepted belief. In our trial, GEL resulted in decreased clot strength (MA) accompanied with unchanged initial fibrin formation (R) and fibrin buildup (K and a), which appears to be attributed to a reduction of functional clot quality, an assumption supported by several in vivo and in vitro studies. [3] [4] [5] 20 The previously suggested primarily fibrin-mediated mechanism of GEL-induced compromise of hemostasis seems to be that GEL has been shown to bind with fibronectin 21 and decrease plasma fibronectin concentration 22 in vivo, which forms covalent cross-linkages and noncovalent associations with fibrin. These GEL-based products may become incorporated into developing clots, thus interfering with clot architecture and mechanics. 6, 23 In addition, GEL appears to inhibit in vitro platelet aggregation induced by activators of the platelet receptor GPIIb-IIIa (adenosine diphosphate, platelet-activating factor, collagen, and epinephrine). 24 Furthermore, in a porcine model, Fries et al demonstrated that the administration of fibrinogen was not only able to restore the impaired clot firmness and clot formation time but also able to reduce blood loss, even in the case of uncontrolled hemorrhage after liver laceration. 25 This theory could also account for the failure to identify these alterations of hemostasis by measurement of conventional clot-based assays, such as PT and aPTT, which use fibrin formation as an end point and ignore subsequent events critical to the formation of a viable clot. Nevertheless, while fibrin polymerization itself is related both to thrombin generation and to the quantity and property of fibrinogen, it remains to be determined whether GEL impairs thrombin formation and how it interferes with the reticular fibrin network. It also remains to be determined whether unspecific binding of denatured collagen to the platelet surface which impairs platelet procoagulant activity is another potential mechanism of GEL-induced impairment of hemostasis.
In our study, as expected, RL showed no negative influence on hemostasis competence in line with the findings of Fries et al. 12 By contrast, others found a hypercoagulability state by hemodilution with RL. 2 The reason for this appears to be an imbalance between natural occurring anticoagulants and activated procoagulants, and a reduction of antithrombin III is probably the primary source of this phenomenon. 26 The discrepancies among these studies indicate that the degree of hemodilution may be crucial for changes in blood coagulation. Furthermore, it is increasingly evident that the pathophysiologic characteristic of in vitro studies on coagulation does not always reflect the in vivo condition. 27 Extrapolation of in vitro data with data found in the clinical setting is difficult, because the endothelial effects, pharmacokinetics, and metabolism 12 of these synthetic colloids are not included and the situation in surgery is not mimicked 27, 28 in the in vitro model. There are several study limitations to our study that need to be noted. First, in the present study, only patients scheduled for gastrectomy were included, because different kinds of surgeries may induce varying effects on hemostasis. Moreover, all 36 patients had gastric cancer which is known to have hypercoagulability and possibly this would mask the changes. Thus, further clinical studies are necessary to fully elucidate the influence of colloid solutions on hemostasis and correlative mechanisms. Second, the possible effect of RL administered in combination with synthetic colloids on hemostasis has been neglected in our study. Third, although assessing the hemostatic alterations by measuring a few coagulation factors and TEG, an indirect method of thrombin measurement, we do not predict what the composite effect of those factor levers will be on the potential of the whole system to generate thrombin.
Conclusions
Intravenous infusion of 30 mL Á kg À1 of 6% HES 130/0.4 or 4% GEL in patients undergoing gastrectomy produced mild coagulation effect. Every colloid solution interferes with the coagulation system in a particular way. Hydroxyethyl starch induces delayed initiation of sufficient thrombin generation to convert fibrinogen to fibrin and impaired platelet function, and GEL induces derangements of fibrin polymerization. These results may be induced from not only hemodilution but also their pharmacological properties.
